[COVID-19 among children and adolescents]

Ugeskr Laeger. 2022 Feb 28;184(9):V11210858.
[Article in Danish]

Abstract

Children and adolescents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are usually asymptomatic or have mild coronavirus disease (COVID-19) with low rates of hospitalization and death. Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe complication of SARS-CoV-2 infection. This paper reviews an excerpt of the literature on disease burden and complications following COVID-19 in children and adolescents aged 0-17 years, in addition to the effects and adverse drug reactions of BNT162b2 and mRNA-1273 vaccinations among children and adolescents aged 5-17 years.

Publication types

  • Review

MeSH terms

  • Adolescent
  • BNT162 Vaccine
  • COVID-19* / complications
  • Child
  • Child, Preschool
  • Hospitalization
  • Humans
  • Infant
  • Infant, Newborn
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome

Substances

  • BNT162 Vaccine

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related